Microbial transformation of diosgenin (1) using Absidia coerulea yielded five new polar metabolites, which were identified as (25R)-spirost-5-en-3β,7β,12β,25α-tetrol (2), (25S)-spirost-5-en-3β,7α,12β,25β-tetrol (3), (25S)-spirost-5-en-3β,7β,12β,25βtetrol (4), (25R)-spirost-5-en-3β,7α,12β,25α-tetrol (5), and (25R)-spirost-5-en-3β,7β,12β,24β-tetrol (6). Their structures were established on the basis of mass spectrometry and multi-dimensional NMR spectroscopy. The characteristic transformations observed were C-7α, C-7β, C-12β, C-24β, C-25α, and C-25β hydroxylation. The cytotoxicity of compounds 1-6 was evaluated against the human myelogenous leukemia K562 cell line and squamous cell carcinoma KB parental cell lines. Compounds 2−6 exhibited weak cytotoxicity against K562 and KB cells and were less potent than the parent compound 1.
Microbial transformation is an important way to diversify structures and to prepare compounds which are difficult to obtain by chemical means [1a−1d] . Diverse reactions on steroids, such as hydroxylation, oxidation, reduction, hydrolysis, isomerization, epimerization, and rearrangement, have been accomplished by microbial conversions. Hydroxylation is possibly the most widespread type of steroid bioconversion [1b] . 11α-, 11β-, 15α-, and 16α-Hydroxylations are presently used in the steroid industry [1c] . Absidia coerulea is well known for hydroxylating steroids and is able to hydroxylate various steroidal structures at the 7α-and 11β-positions to produce optically active alcohols [1e−1f] . Diosgenin [(25R)-spirost-5-en-3β-ol, 1] is an important starting material in the pharmaceutical industry for the production of steroid drugs [2a−2b] . In recent years, several preclinical studies have demonstrated the anticancer effects of diosgenin (1), such as apoptosis induction in human erythroleukemia cell lines [2c−2f] and human colon cancer cells in vitro [2g−2i].
Herein we focus our research on investigating the ability of A. coerulea to transform diosgenin (1). The five new metabolites 2−6 were isolated from the broth. Their structures were determined by spectroscopic methods. The characteristic transformations observed were C-7α, C-7β, C-12β, C-24β, C-25α, and C-25β hydroxylation. In addition, compounds 1−6 were preliminarily assayed for their cytotoxic activities (calcd 463.3054) , indicating that three additional oxygens were present in 2 as compared with 1. The 1 H and 13 C NMR data (Tables 1 and 2) of 2 revealed the presence of two tertiary carbons at δ C 73.4 and 80.0 and one oxygenated quaternary carbon at δ C 86.2, consistent with three new hydroxyl groups. The first hydroxyl moiety was attributed to C-7 (δ 73.4), which was verified by the HMBC correlations of H-8 (δ 1.62, m) and H-9 (δ 1.28, m) to C-7. The β-configuration of 7-OH was established by comparison of the C-7 chemical shift in the 13 C NMR spectrum of 2 with those reported for sterols with a 5-ene-3β,7-diol substructure (7α-OH, δ C 65.3; 7β-OH, δ C 73.3) [3a] . The second hydroxyl group was OH-12, confirmed by the long-range correlations of C-12 NPC Natural Product Communications 2010 Vol. 5 No. 3 373 -376 Compounds 4 and 5 were also obtained as white amorphous solids. The HRESIMS of 4 and 5 were both in accordance with the molecular formula, C 27 H 42 O 6 . The similarity of the 1 H and 13 C NMR spectroscopic data (Tables 1 and 2) of compounds 2−5 suggested that they are diastereoisomers. The structures of 4 and 5 were confirmed by their 2D NMR data. Thus, compounds 4 and 5 were elucidated as (25S)-spirost-5en-3β,7β,12β,25β-tetrol and (25R)-spirost-5-en-3β,7α,12β,25α-tetrol, respectively.
Compound 6 was isolated as a white amorphous powder. Its molecular formula was determined to be C 27 H 42 O 6 based on the [M+H] + peak at m/z 463.3060 (calcd 463.3054) in the HRESIMS, similar to that of 2. The only difference between 6 and 2 was that the hydroxyl group in 6 was positioned at C-24 instead of C-25, as in 2, which was elucidated by the HMBC (Table 1) , the proton signal at δ 3.50 (H-24, td, J = 10.2, 5.4 Hz) showed that the proton has an αconfiguration. Therefore, compound 6 was characterized as (25R)-spirost-5-en-3β,7β,12β,24β-tetrol.
A 4-day incubation of A. coerulea with diosgenin (1) resulted in the formation of five hydroxylated products 2−6. The results here imply that A. coerulea is able to hydroxylate 1 at the 7α-, 7β-, 12β-, and 24β-, 25α-and 25β-positions. The secondary and tertiary hydroxylation of the substrate indicated that the enzyme(s) present in A. coerulea can bind on both the front and rear sides of the steroidal skeleton [3c]. Selective hydroxylation is a key step in the industrial manufacture of valuable steroids. 12β-Hydroxylation is difficult to achieve by chemical means and this fungal transformation has potential to produce useful compounds as starting materials for the production of 12β-hydroxyandrostenes [3d].
Compounds 1−6 were evaluated for their cytotoxicity against the human myelogenous leukemia K562 cell line and squamous cell carcinoma KB parental cell lines using the MTT assay. Compounds 2−6 exhibited IC 50 values ranging from 35.6 to 46.8 μM against K562 or KB cells. The bioassay results indicate that the transformed products had lower activity than the parent compound due to possible detoxication of exogenous steroids. 
Microbial metabolism of diosgenin:
Screening scale biotransformation of 1 by A. coerulea was carried out in 100 mL Erlenmeyer flasks containing 30 mL of potato medium. Microorganisms were transferred into the flasks from slants. The flasks were placed on rotary shakers, operating at 180 rpm at 28°C. The substrate was dissolved in hot ethanol with a concentration of 5 mg/mL. After 36 h incubation, 0.6 mL of the solution was added into the fermentation flasks and these were maintained under the same conditions for an additional 96 h. Culture controls consisted of fermentation blanks in which microorganisms were grown without substrate, but with the same amount of ethanol. Substrate controls consisted of sterile medium containing the same amount of substrate and were incubated under the same conditions. When the fermentation was finished, the broths were filtered and the resulting filtrates were extracted with the same volume of ethyl acetate 3 times. The cells were refluxed with ethyl acetate. The combined ethyl acetate extracts were evaporated to dryness under reduced pressure. The residues were dissolved in methanol and analyzed by TLC. All fermentations were duplicated and showed good reproducibility. Preparative scale biotransformation of 1 by A. coerulea was carried out in 250 mL Erlenmeyer flasks containing 150 mL of potato medium. A total of 300 mg of 1 was transformed. The following procedures were the same as in the screening scale biotransformations. The resulting brown gum weighed 1.5 g.
Isolation of biotransformation products:
The brown gum (1.3 g) was dissolved in methanol, absorbed on 1.8 g silica gel and subjected to CC (silica gel; CHCl 3 /MeOH 1:0→0:1) to provide 6 fractions (Fr. A-Fr. F). Frs C and D were further purified by HPLC using 50% and 60% MeOH/H 2 O as the mobile phase (flow rate 1.0 mL/min). Elution of products was monitored on-line by a UV detector at 210 nm. Compounds 2 (6.4 mg), 3 (5.0 mg), 4 (5.0 mg), 5 (4.5 mg), and 6 (4.5 mg) were obtained as white, amorphous powder.
(25R)-Spirost-5-en-3β,7β,12β,25α-tetrol (2) [α] D : −28.6 (c 0.49, MeOH). Rf : 0.4 (CHCl 3 -MeOH, 10:1 (25S)-Spirost-5-en-3β,7α,12β,25β-tetrol (3) [α] D : −99.2 (c 0.32, MeOH). Rf: 0.4 (CHCl 3 -MeOH, 10:1). IR (KBr): 3424, 2929, 2874, 2855, 1664, 1457, 1376, 1100, 1053, 1036, 984, 938 , 891 cm -1 . 1 H and 13 C NMR: Tables 1 and 2. 
